Skip to content
Putting Americans First: No medicine is more expensive than the one patients can’t access
The most notable differences between the pharmaceutical market in the U.S. and those ...
Read More
BIO Coffee Chat looks at patient access after three years of the IRA
It has been three years since the Inflation Reduction Act (IRA) was signed ...
Read More
Riboway Therapeutics: Resilience, RNA, and redefining the undruggable
At this year’s BIO International Convention in Boston, Riboway Therapeutics emerged as the winner ...
Read More
Startup Stadium: Tezcat Biosciences targets common cancer mutation
A Rat sarcoma (RAS) mutation is an oncogene, a gene that causes cancer ...
Read More
Psoriasis awareness: The condition is more than skin deep
Over 8 million people in the U.S., and 125 million worldwide, live with ...
Read More
BIO 2025: As M&A slows, biotechs need to show good data
M&A in biotech has slowed from its peak in 2023 but there are ...
Read More
EDITORS' CHOICE
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the Board ...
Read More
LATEST NEWS
BIO's View
Putting Americans First: No medicine is more expensive than the one patients can’t access
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the ability ...
Federal Policy
BIO Coffee Chat looks at patient access after three years of the IRA
It has been three years since the Inflation Reduction Act (IRA) was signed into law. “We have definitively seen negative impacts on patient access, and ...
BIO Events
Riboway Therapeutics: Resilience, RNA, and redefining the undruggable
At this year’s BIO International Convention in Boston, Riboway Therapeutics emerged as the winner of the 2025 BIO Start-Up Stadium seed-stage category. For founder and CEO ...
BIO Events
Startup Stadium: Tezcat Biosciences targets common cancer mutation
A Rat sarcoma (RAS) mutation is an oncogene, a gene that causes cancer when mutated. The RAS is the most commonly mutated oncogene in human ...
Federal Policy
Psoriasis awareness: The condition is more than skin deep
Over 8 million people in the U.S., and 125 million worldwide, live with psoriasis—about 2–3% of the population. Far from being a simple cosmetic condition, ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
Life sciences job report shows growth slowing, but firms still invest in talent
As the United States has long been a life sciences leader, the health of the life sciences sector is a ...
Read More
International
Bio's View
Putting Americans First: No medicine is more expensive than the one patients can’t access
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the ...
Read More
